Janux Therapeutics (JANX) Projected to Post Earnings on Wednesday

Janux Therapeutics (NASDAQ:JANX) will likely be releasing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Janux Therapeutics to post earnings of ($0.60) per share and revenue of $3.0710 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 6:00 PM ET.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.07). On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Stock Performance

JANX opened at $29.76 on Wednesday. The business has a 50 day moving average price of $24.44 and a 200 day moving average price of $25.32. The firm has a market cap of $1.79 billion, a P/E ratio of -16.53 and a beta of 2.82. Janux Therapeutics has a twelve month low of $21.73 and a twelve month high of $71.71.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Osaic Holdings Inc. raised its stake in shares of Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Janux Therapeutics by 185.1% in the second quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock valued at $177,000 after purchasing an additional 4,982 shares in the last quarter. American Century Companies Inc. acquired a new position in shares of Janux Therapeutics in the second quarter valued at $261,000. Finally, AQR Capital Management LLC raised its stake in shares of Janux Therapeutics by 71.7% in the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock valued at $262,000 after purchasing an additional 4,059 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Guggenheim assumed coverage on Janux Therapeutics in a report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 price target for the company. Barclays assumed coverage on Janux Therapeutics in a report on Wednesday, September 17th. They set an “overweight” rating and a $47.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Wednesday, October 8th. Raymond James Financial assumed coverage on Janux Therapeutics in a report on Friday, July 11th. They set an “outperform” rating and a $65.00 price target for the company. Finally, Truist Financial assumed coverage on Janux Therapeutics in a report on Wednesday, September 10th. They set a “buy” rating and a $100.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Janux Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $79.08.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.